Fully human broadly neutralizing antibody against the respiratory syncytial virus (RSV), an optimized natively paired human monoclonal antibody isolated from an elite donor. The prophylactic candidate displays potent and broad neutralizing activities against diverse RSV clinical isolates. Ongoing next-generation cocktail includes dual therapeutic antibodies targeting distinct epitopes.
First-in-class and best-in-class broadly neutralizing antibody cocktail against the Ebolaviruses. The therapeutic cocktail provides full protection against all pathogenic ebolaviruses in mice, guinea pigs, ferrets, and non-human primates. The research data and detailed descriptions are available on Cell and Nature Communications.
Broadly neutralizing antibody cocktail isolated from vaccinated non-human primates and elite donors. Targeted therapeutics against toxins released by Staphylococcal bacteria. Potential passive immunotherapy for the prevention and treatment of Staphylococcal bloodstream infections.
Fully human anti-tumor antibody isolated from rare elite controllers. Targeted therapeutic to a specific tumor neoantigen (cancer-specific broadly reactive mAb). Potential passive immunotherapy for the treatment of neoantigen positive patients.